Wird geladen...
Sacubitril/valsartan in heart failure: latest evidence and place in therapy
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) r...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Chronic Dis |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076745/ https://ncbi.nlm.nih.gov/pubmed/27803793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622316665350 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|